In July, American pharmaceutical giant Merck completed the $3 billion acquisition of a biotech firm named Eyebio. The deal included a hefty upfront cash payment of $1.3 billion.
The centrepiece of the acquisition was EYE103, a cutting-edge, antibody-based drug with remarkable potential to treat retinal diseases caused by vascular leakage, such as neovascular age-related macular degeneration (NVAMD), diabetic macular oedema (DME), and familial exudative vitreoretinopathy (FEVR).
NVAMD affects over 200 million people globally, while millions more with type-1 or type-2 diabetes are at risk of developing DME. FEVR is a disorder that can lead to progressive vision loss. These conditions had no cures and EYE103 offers hope as a first drug of its kind. Its innovative antibody activates the Wnt-signalling pathway-a protein network that transmits cellular information-strengthening blood vessel integrity in the eye and preventing fluid build-up in the retina.
The antibody molecule in EYE103 is one of thousands of engineered antibodies-each with the potential to become future drugs for a range of serious illnesses, from cancer to rare diseases originating from the lab of Canadian researcher Sachdev Sidhu.
The 55-year-old recently returned to his country of origin for an event. I met him for a teatime interview at a bistro beside the serene artificial lake at the Taj Kumarakom Resort in Kerala. I was expecting a formally attired, jargon-spewing man of science. But, my preconceived notions were quickly shattered. Sidhu, the author of more than 200 scientific papers, a co-inventor on more than 50 patents granted by or filed with the US patent office, and a professor and entrepreneurin-residence at the University of Waterloo, arrived in shorts and a round-neck T-shirt and ordered a glass of wine. In response to one of my early questions, he quoted American rapper Snoop Dogg.
Diese Geschichte stammt aus der December 01, 2024-Ausgabe von THE WEEK India.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der December 01, 2024-Ausgabe von THE WEEK India.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Efficiency and innovation
As health care evolves, professionals must employ innovative methods to refine their skills
Level up
Only 30 per cent of needy patients are able to undergo transplant in India; we need more dedicated transplant centres
HOPE STEMS FROM A CELL
While stem cell therapies have shown success in treating blood disorders, orthopaedic ailments, autoimmune diseases and eye issues, there is hope that they can one day treat patients with heart disease, blindness, Parkinson's, HIV, diabetes and spinal cord injuries
Mind matters
Your mindset can limit or expand your physical ability
Cutting edge
Would you go under the knife if a robot was the one holding it? Or would you say, \"No way, I need a human touch\"? You might have to decide soon because a robot that can imitate skilled human surgeons is already here.
The smallest cut
Minimally invasive surgeries have a bright future, with virtual reality and 3D procedures offering greater precision and AI on the horizon
Signalling a revolution
Canadian scientist and entrepreneur Sachdev Sidhu is focused on bringing cutting-edge antibody engineering to his country of origin
Wellness on demand
Starting as a doctor-patient chat platform, Medibuddy has evolved to be India's largest on-demand, full-stack digital health care platform
HEARING AND VISION LOSS LINKED TO HEART DISEASE AND STROKE
A CHINESE STUDY PUBLISHED IN THE JOURNAL of the American Heart Association suggests that middle aged and older adults with sensory impairments, specifically hearing and vision loss, have an elevated risk of cardiovascular diseases, including stroke and heart attacks.
PETTICOAT CANCER AND THE SARI LINK
TYING YOUR UNDERSKIRT (petticoat) tightly around the waist when wearing a sari, can lead to \"petticoat cancer\" or \"sari cancer,\" as it was previously called. Tying the underskirt too tightly can cause constant cord friction that can lead to chronic inflammation, skin ulceration and, in rare cases, skin cancer.
